John Johnson
Director at Axogen, Inc. (AXGN); Director at Xeris Biopharma Holdings, Inc. (XERS)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $2.9M
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Jun 5SEC | XERSXeris Biopharma Holdings, Inc. | Sell Plan | 15,000683,083 held (−2%) | $6.09 | $91K | +72.1% |
| May 8SEC | AXGNAxogen, Inc. | Sell | 11,050 | $43.26 | $478K | -16.5% |
| Dec 19SEC | XERSXeris Biopharma Holdings, Inc. | Sell | 135,400698,083 held (−16%) | $7.22 | $978K | +45.2% |
| Dec 10SEC | AXGNAxogen, Inc. | Sell | 11,80213,141 held (−47%) | $31.26 | $369K | +15.6% |
| Dec 10SEC | AXGNAxogen, Inc. | Sell | 11,89113,141 held (−48%) | $31.22 | $371K | +15.7% |
| Dec 10SEC | AXGNAxogen, Inc. | Sell | 8,54513,141 held (−39%) | $29.98 | $256K | +20.5% |
| Dec 10SEC | AXGNAxogen, Inc. | Sell | 13,141 | $29.98 | $394K | +20.5% |
- Sell
Director John Johnson sold $91K of XERS at $6.09 — pre-scheduled 10b5-1 plan sale.
- Sell
Director John Johnson sold $369K of AXGN at $31.26 — cuts the stake by 47%.
- Sell
Director John Johnson sold $371K of AXGN at $31.22 — cuts the stake by 48%.
- Sell
Director John Johnson sold $256K of AXGN at $29.98 — cuts the stake by 39%.